Cargando…
Measuring windows of selection for anti-malarial drug treatments
BACKGROUND: The long half-lives of malaria ‘partner’ drugs are a potent force selecting for drug resistance. Clinical trials can quantify this effect by estimating a window of selection (WoS), defined as the amount of time post-treatment when drug levels are sufficiently high that resistant parasite...
Autores principales: | Kay, Katherine, Hastings, Ian M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521485/ https://www.ncbi.nlm.nih.gov/pubmed/26228915 http://dx.doi.org/10.1186/s12936-015-0810-4 |
Ejemplares similares
-
Estimating the window of selection of antimalarial drugs using field data
por: Winter, Katherine, et al.
Publicado: (2012) -
Policy options for deploying anti-malarial drugs in endemic countries: a population genetics approach
por: Antao, Tiago, et al.
Publicado: (2012) -
Spread of anti-malarial drug resistance: Mathematical model with implications for ACT drug policies
por: Pongtavornpinyo, Wirichada, et al.
Publicado: (2008) -
Pharmacological considerations in the design of anti-malarial drug combination therapies – is matching half-lives enough?
por: Hastings, Ian M, et al.
Publicado: (2014) -
Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling
por: Hodel, Eva Maria, et al.
Publicado: (2014)